Recent:
Savaliya
Low
Wan
Prasoppokakorn. Submit updates/corrections .
|
Apr 25
|
Andrographolide for COVID-19: real-time meta analysis of 7 studies | |
| Statistically significant lower risk is seen for recovery. 2 studies from 2 independent teams in 2 countries show statistically significant improvements. Meta analysis using the most serious outcome reported shows 27% [-8‑50%] .. | ||
|
Feb 22
|
et al., bioRxiv, doi:10.1101/2024.02.21.581396 | The wide spectrum anti-inflammatory activity of andrographolide in comparison to NSAIDs: a promising therapeutic compound against the cytokine storm |
| In vitro study showing that andrographolide exhibits broad anti-inflammatory and cytokine inhibiting activity against lipopolysaccharide (LPS) and interferon-γ induced inflammation in murine RAW264.7 and human THP-1 macrophage cell lines... | ||
|
Feb 21
|
et al., Scientific Reports, doi:10.1038/s41598-024-54722-5 | Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level |
| In Vitro and mouse study showing that andrographolide and baicalin have synergistic antiviral effects against SARS-CoV-2. Andrographolide and baicalin inhibited binding between the SARS-CoV-2 spike protein and ACE2 receptor in human cells.. | ||
|
Feb 2
|
et al., OBM Integrative and Complementary Medicine, doi:10.21926/obm.icm.2401013 | Efficacy and Safety of Andrographolide and Favipiravir Versus Favipiravir Monotherapy in Patients with Mild COVID-19 Infection: A Multicenter Randomized Controlled Trial |
| 37% improved recovery (p=0.005). Randomized controlled trial of 82 mild COVID-19 outpatients showing significantly greater reduction in cough and lower inflammatory markers at day 7. Symptomatic improvement was significant at day 7 when combining all symptoms reported, b.. | ||
|
Dec 21
2023 |
et al., 2023 IEEE 5th Eurasia Conference on Biomedical Engineering, Healthcare and Sustainability, doi:10.3390/engproc2023055081 | Dynamic Model of Andrographolide Therapy for COVID-19 |
| Pharmacokinetic and pharmacodynamic modeling of andrographolide for COVID-19. The model suggests that a dose of 60mg per day of andrographolide is optimal for reducing viral load and infection. The model incorporates the diffusion of the .. | ||
|
Dec 7
2023 |
et al., Journal of Ethnopharmacology, doi:10.1016/j.jep.2023.117535 | Efficacy and safety of Link Natural Sudarshana, an Ayurvedic herbal preparation in COVID-19 patients: A phase II multicenter double-blind randomized placebo-controlled trial |
| RCT 171 hospitalized COVID-19 patients in Sri Lanka, showing improved viral clearance and recovery, without statistical significance, for treatment with Link Natural Sudarshana (LNS). LNS is an Ayurvedic herbal preparation containing 49 m.. | ||
|
Nov 23
2023 |
et al., Research in Pharmaceutical Sciences, doi:10.4103/1735-5362.389947 | Andrographis paniculata extract versus placebo in the treatment of COVID-19: a double-blinded randomized control trial |
| 51% lower progression (p=0.25) and 8% improved recovery (p=0.33). RCT 165 low-risk mild COVID-19 patients in Thailand receiving either 180mg/day of Andrographis paniculata extract or placebo for 5 days. No significant difference was found between groups for disease progression, though A. paniculata show.. | ||
|
Nov 15
2023 |
et al., Journal of Ayurveda and Integrative Medicine, doi:10.1016/j.jaim.2023.100778 | Effectiveness of ayurvedic formulation, NAOQ19 along with standard care in the treatment of mild-moderate COVID-19 patients: A double blind, randomized, placebo-controlled, multicentric trial |
| 13% shorter hospitalization (p=0.05) and 12% faster viral clearance (p=0.02). RCT 150 mild-moderate COVID-19 patients showing faster viral clearance and shorter hospitalization with NAOQ19, a polyherbal formulation containing 13 antiviral/antinflammatory compounds. NAOQ19 ingredients include curcumin, andrographis,.. | ||
|
Nov 13
2023 |
et al., Scientific Reports, doi:10.1038/s41598-023-46249-y | Inhibitory efficiency of Andrographis paniculata extract on viral multiplication and nitric oxide production |
| In Vitro study analyzing the antiviral and anti-inflammatory properties of extracts and fractions from Andrographis paniculata, against herpes simplex virus-1 (HSV-1) and influenza A virus H3N2 as surrogates for COVID-19. The results show.. | ||
|
Sep 16
2023 |
et al., Natural Product Communications, doi:10.1177/1934578X231188861 | In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds |
| In vitro study showing that of 9 phenolic compounds tested, only curcumin inhibited SARS-CoV-2 cytopathic effects in infected monkey kidney Vero E6 cells. Curcumin showed antiviral activity against wildtype, alpha, delta, and omicron vari.. | ||
|
Aug 22
2023 |
et al., Pharmaceuticals, doi:10.3390/ph16091196 | Efficacy of Kan Jang® in Patients with Mild COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial |
| 71% lower progression (p=0.03), 70% improved recovery (p=0.07), and 41% faster viral clearance (p=0.12). RCT 140 mild COVID-19 patients treated within 3 days of onset, showing lower progression and improved recovery with Kan Jang (andrographis + eleuthero). | ||
|
Aug 12
2023 |
et al., Phytomedicine, doi:10.1016/j.phymed.2023.155018 | Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) |
| 86% lower need for oxygen therapy (p=0.24), 37% improved recovery (p=0.28), and 5% worse viral clearance (p=0.46). RCT 146 mild/moderate COVID-19 patients in Thailand, showing no significant difference in clinical outcomes. There were very few serious outcomes. | ||
|
Jun 30
2023 |
et al., Phytomedicine, doi:10.1016/j.phymed.2023.154753 | The effects and mechanisms of the anti-COVID-19 traditional Chinese medicine, Dehydroandrographolide from Andrographis paniculata (Burm.f.) Wall, on acute lung injury by the inhibition of NLRP3-mediated pyroptosis |
| In Vitro and mouse study investigating the potential therapeutic effects of dehydroandrographolide (Deh), a compound from the herb Andrographis paniculata, in models of acute lung injury caused by COVID-19 infection. Deh reduced inflammat.. | ||
|
May 31
2023 |
et al., Archives of Internal Medicine Research, doi:10.26502/aimr.0146 | Effect of Andrographis paniculata Treatment for Nonimmune Patients with Early-Stage COVID-19 on the Prevention of Pneumonia: A Retrospective Cohort Study |
| 98% lower progression (p<0.0001). Retrospective 528 asymptomatic/mild patients in Thailand, showing lower progression to pneumonia with andrographis treatment. | ||
|
Feb 28
2023 |
et al., Phytomedicine Plus, doi:10.1016/j.phyplu.2022.100398 | A randomized controlled pilot study of add-on therapy of CIM-MEG19 (standardized Andrographis paniculata formulation) in mild to moderate COVID-19 |
| 91% lower progression (p=0.05), 33% faster recovery (p<0.0001), and 6% improved viral clearance (p=1). 80 mild/moderate hospitalized COVID-19 patients in India, 40 treated with CIM-MEG19 (standardized Andrographis paniculata formulation), showing faster recovery, lower progression, and favorable changes in inflammatory markers, however the.. | ||
|
Feb 21
2023 |
et al., AYU (An International Quarterly Journal of Research in Ayurveda), doi:10.4103/ayu.ayu_92_22 | Safety and efficacy of COROPROTECT kit as an add-on therapy in the management of mild-to-moderate COVID-19: A randomized, placebo-controlled trial |
| 86% improved recovery (p<0.0001) and 53% improved viral clearance (p<0.0001). RCT with 300 mild to moderate hospitalized COVID-19 patients, showing faster recovery, faster viral clearance, and a reduction in inflammatory markers with COROPROTECT, which includes curcumin, andrographis, and several additional treatme.. | ||
|
Dec 31
2022 |
et al., OSIR, 15:4 | SARS-CoV-2 Clearance from Andrographis paniculata, Boesenbergia rotunda, and Favipiravir among Mild COVID-19 Cases in Klong Prem Central Prison during Mid-2021: a Retrospective Study |
| 19% improved viral clearance (p=0.61). Retrospective 120 patients in Thailand, showing improved viral clearance with andrographis compared with favipiravir. | ||
|
Sep 22
2022 |
et al., International Journal of Molecular Sciences, doi:10.3390/ijms231911131 | Molecular Docking and In-Silico Analysis of Natural Biomolecules against Dengue, Ebola, Zika, SARS-CoV-2 Variants of Concern and Monkeypox Virus |
| In Silico study showing that the phytochemical andrographolide derived from Andrographis paniculata binds strongly to the spike proteins of six SARS-CoV-2 variants, including the B.1.1.7 UK, B.1.351 South African, P.1 Japan/Brazil, B.1.42.. | ||
|
Aug 10
2022 |
et al., Frontiers in Medicine, doi:10.3389/fmed.2022.947373 | Use of Andrographis paniculata (Burm.f.) Wall. ex Nees and risk of pneumonia in hospitalised patients with mild coronavirus disease 2019: A retrospective cohort study |
| 26% higher progression (p=0.4). Retrospective 605 hospitalized patients in Thailand, showing higher progression with andrographis, without statistical significance. | ||
|
Jul 13
2022 |
et al., Molecules, doi:10.3390/molecules27144479 | A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead Compounds for COVID-19 Drug Discovery |
| Review of Andrographis paniculata extracts and compounds like andrographolide with antiviral, anti-inflammatory, and immunomodulatory properties that could help treat COVID-19 symptoms and progression. In silico studies suggest these comp.. | ||
|
May 30
2022 |
et al., NCT05178173 | Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19 |
| Estimated 3,060 patient andrographolide early treatment RCT with results not reported over 1.5 years after estimated completion. | ||
|
Dec 27
2021 |
et al., Research Square, doi:10.21203/rs.3.rs-1165680/v1 | An integrative approach to clinical recovery for COVID-19 patients using an Ayurvedic formulation: A multicentric double-blind randomized control trial |
| 89% improved recovery (p=0.05) and 24% improved viral clearance (p=0.47). Small RCT with 39 patients treated with NOQ19 and 37 placebo patients, showing improved recovery, without statistical significance. NOQ19 has multiple ingredients including curcumin, andrographis, and antiandrogen glycyrrhiza glabra. | ||
|
Jul 11
2021 |
et al., Archives of Internal Medicine Research, doi:10.26502/aimr.0125 (date from preprint) | Efficacy and Safety of Andrographis Paniculata Extract in Patients with Mild COVID-19: A Randomized Controlled Trial |
| 86% lower progression (p=0.11) and 40% improved viral clearance (p=0.11). RCT 63 mild COVID-19 patients showing lower progression and improved viral clearance with andrographis, without statistical significance. | ||
|
May 12
2021 |
et al., Phytotherapy Research, doi:10.1002/ptr.7141 | Efficacy and safety of Xiyanping injection in the treatment of |
| 92% lower severe cases (p=0.03), 48% improved recovery (p=0.008), and 53% improved viral clearance (p=0.0001). RCT 130 hospitalized COVID-19 patients in China, showing lower progression and improved recovery with Xiyanping injection (9-dehydro-17-hydro-andrographolide and sodium 9-dehydro-17-hydro-andrographolide-19-yl sulfate, which are derived f.. | ||
|
Oct 16
2020 |
et al., Future Journal of Pharmaceutical Sciences, doi:10.1186/s43094-020-00126-x | Activity of phytochemical constituents of Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach |
| In Silico study of several phytochemical compounds from Curcuma longa (turmeric) and Andrographis paniculata for their potential activity against COVID-19 by targeting the SARS-CoV-2 main protease. Molecular docking analysis found the tur.. | ||
|
Jun 18
2020 |
et al., Research Square, doi:10.21203/rs.3.rs-35800/v1 | The role of andrographolide and its derivative in COVID-19 associated proteins and immune system |
| In Silico study showing that andrographolide and its derivative 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata may be beneficial for COVID-19 by binding to key SARS-CoV-2 proteins and modulating immune pathways. Auth.. | ||
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.